Last 44 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 227.83 | — | — | 3.31 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 5.23 | — | 3.96 | 1.55 | 3.06 | 4.11 | 4.65 | 4.54 | 5.95 | 10.49 | 12.39 | 10.36 | 28.61 |
| — | — | -14.9% | -65.7% | -48.7% | -60.8% | -62.5% | -56.2% | -79.2% | -75.0% | -80.4% | -87.7% | -61.3% | |
| P/B Ratio | 13.96 | 12.40 | 8.55 | 7.11 | 13.96 | 16.71 | 17.30 | 15.07 | 17.98 | 27.10 | 37.31 | 19.70 | 31.47 |
| — | -25.8% | -50.6% | -52.8% | -22.4% | -38.4% | -53.6% | -23.5% | -42.9% | +48.7% | +10.8% | -18.7% | +118.3% | |
| P/FCF | 116.63 | — | — | 6.58 | 124.06 | — | 51.11 | 26.20 | — | — | — | — | — |
| — | — | — | -74.9% | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 92.46 | — | — | 3.19 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 95.06 | — | — | 3.13 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Apellis Pharmaceuticals, Inc.'s operating margin was 13.8% in Q1 2026, up 39.4 pp QoQ and up 63.7 pp YoY. The trailing four-quarter average of 4.6% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.8% | 78.9% | 85.1% | 94.7% | 92.1% | 79.4% | 80.8% | 83.0% | 88.2% | 88.0% | 86.4% | 79.7% | 91.2% |
| — | -0.7% | +5.4% | +14.1% | +4.4% | -9.8% | -6.5% | +4.1% | -3.3% | +6.6% | -0.8% | -15.0% | -8.4% | |
| Operating Margin | 5.5% | 13.8% | -25.6% | 48.7% | -18.6% | -50.0% | -12.3% | -24.0% | -14.7% | -36.0% | -57.7% | -124.2% | -126.8% |
| — | +127.6% | -107.8% | +302.6% | -26.5% | -38.7% | +78.7% | +80.7% | +88.4% | +90.8% | +92.0% | +82.1% | +86.1% | |
| Net Margin | 2.2% | 9.7% | -29.5% | 47.0% | -23.6% | -55.3% | -17.1% | -29.2% | -18.9% | -38.5% | -60.5% | -127.0% | -128.5% |
| — | +117.6% | -72.4% | +261.2% | -25.2% | -43.4% | +71.7% | +77.0% | +85.3% | +90.3% | +91.7% | +85.4% | +86.6% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 7.5% | 4.8% | -15.3% | 77.4% | -26.3% | -47.0% | -15.6% | -22.9% | -14.2% | -28.8% | -41.5% | -48.6% | -32.2% |
| — | +110.1% | +2.1% | +437.8% | -85.4% | -63.0% | +62.4% | +52.8% | +56.0% | +52.9% | +40.3% | +18.5% | +17.7% | |
| ROA | 2.3% | 1.7% | -5.5% | 22.9% | -5.2% | -10.9% | -4.1% | -6.4% | -4.3% | -8.2% | -11.0% | -16.2% | -12.9% |
| — | +115.9% | -35.8% | +460.8% | -19.3% | -33.0% | +63.1% | +60.7% | +66.3% | +59.9% | +45.8% | +20.7% | +11.3% | |
| ROIC | 12.3% | 7.8% | -9.8% | 51.3% | -9.4% | -22.2% | -6.6% | -10.3% | -8.6% | -107.6% | — | — | — |
| — | +134.9% | -48.6% | +599.2% | -9.0% | +79.3% | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Apellis Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 4.3x — elevated, raising questions about debt serviceability. The current ratio has weakened 11.1% YoY to 3.63x, tightening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.31 | 0.27 | 1.31 | 1.18 | 3.01 | 2.86 | 2.06 | 1.98 | 1.80 | 0.72 | 0.57 | 0.47 | 0.32 |
| — | -90.4% | -36.1% | -40.3% | +67.4% | +295.7% | +260.5% | +320.6% | +459.6% | +166.2% | -14.1% | +27.9% | -49.2% | |
| Debt / EBITDA | 8.53 | 4.29 | — | 2.13 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.14 | 3.63 | 3.14 | 3.54 | 3.77 | 4.08 | 4.25 | 4.36 | 5.08 | 3.77 | 3.10 | 4.29 | 5.11 |
| — | -11.1% | -26.3% | -18.7% | -25.9% | +8.2% | +37.4% | +1.6% | -0.4% | -45.2% | -27.9% | -40.4% | -32.6% | |
| Quick Ratio | 2.70 | 3.16 | 2.70 | 3.10 | 3.16 | 3.62 | 3.81 | 3.73 | 4.12 | 3.02 | 2.50 | 3.67 | 4.49 |
| — | -12.6% | -29.2% | -16.7% | -23.3% | +19.8% | +52.1% | +1.5% | -8.2% | -51.8% | -33.8% | -45.1% | -37.5% | |
| Interest Coverage | 1.54 | 2.57 | -4.41 | 20.18 | -2.74 | -7.32 | -2.13 | -3.54 | -3.01 | -8.51 | -10.77 | -18.15 | -15.60 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 44 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying APLS stock.
Apellis Pharmaceuticals, Inc.'s current P/E is 227.8x. The average P/E over the last 1 quarters is 3.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Apellis Pharmaceuticals, Inc.'s current operating margin is 5.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Apellis Pharmaceuticals, Inc.'s business trajectory between earnings reports.